News headlines about Eli Lilly And Co (NYSE:LLY) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eli Lilly And Co earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.0801632681705 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern’s rankings:
- AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status (finance.yahoo.com)
- Barclays Reiterates Buy Rating for Eli Lilly And Co (LLY) (americanbankingnews.com)
- Arrowhead touts hep B data, shares rocket up; Eli Lilly’s animal health unit files big IPO (endpts.com)
- UPDATE 1-Lilly’s Elanco unit expects IPO to raise up to $1.45 bln (feeds.reuters.com)
- Eli Lilly’s Elanco sets IPO terms to raise up to $1.45 billion before options (marketwatch.com)
NYSE LLY opened at $107.03 on Friday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $107.24. The firm has a market cap of $113.54 billion, a P/E ratio of 25.01, a PEG ratio of 1.76 and a beta of 0.28.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The company had revenue of $6.36 billion for the quarter, compared to the consensus estimate of $6.05 billion. During the same quarter last year, the business posted $1.11 EPS. Eli Lilly And Co’s revenue for the quarter was up 9.1% on a year-over-year basis. analysts forecast that Eli Lilly And Co will post 5.47 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 10th. Investors of record on Wednesday, August 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.10%. The ex-dividend date is Tuesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.
LLY has been the topic of a number of research analyst reports. Credit Suisse Group set a $82.00 target price on Eli Lilly And Co and gave the company a “hold” rating in a report on Tuesday, May 15th. Barclays set a $98.00 target price on Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, May 22nd. Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Wednesday, May 23rd. ValuEngine raised Eli Lilly And Co from a “sell” rating to a “hold” rating in a report on Wednesday, May 23rd. Finally, Cantor Fitzgerald initiated coverage on Eli Lilly And Co in a report on Thursday, June 7th. They issued an “overweight” rating and a $100.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and a consensus price target of $100.69.
In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction on Tuesday, July 31st. The stock was sold at an average price of $98.74, for a total transaction of $20,241,700.00. Following the sale, the insider now owns 121,121,794 shares of the company’s stock, valued at approximately $11,959,565,939.56. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $105.57, for a total value of $63,342.00. Following the sale, the insider now directly owns 3,530 shares in the company, valued at approximately $372,662.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,732,813 shares of company stock worth $168,655,414. 0.11% of the stock is currently owned by company insiders.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.